Stocktoria
REGENTIS BIOMATERIALS LTD. RGNT
NYSE · stock · Orthopedic, Prosthetic & Surgical Appliances & Supplies
REGENTIS BIOMATERIALS LTD. financials (annual)
Bars are annual figures from 2024 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 |
|---|---|---|
| Operating income | -$7.0M | $932,000 |
| Net income | -$13.6M | $4.8M |
| EPS (diluted) | $-24.16 | $1.72 |
| Operating cash flow | -$1.4M | -$641,000 |
| Cash & equivalents | $7.4M | — |
| Total assets | $7.6M | $482,000 |
| Total liabilities | $2.9M | $6.5M |
| Shareholders' equity | $4.7M | -$41.1M |
Growth · year-over-year
| Metric | FY2025 | FY2024 |
|---|---|---|
| Net income growth | -384.3% | — |
| EPS growth | -1504.7% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.